

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/313015623>

# Silica nanoparticles induce cardiotoxicity interfering with energetic status and Ca<sup>2+</sup> handling in adult rat cardiomyocytes

Article in *AJP Heart and Circulatory Physiology* · January 2017

DOI: 10.1152/ajpheart.00564.2016

CITATIONS

6

READS

134

13 authors, including:



**Enrique Guerrero-Beltrán**

Tecnológico de Monterrey

20 PUBLICATIONS 414 CITATIONS

[SEE PROFILE](#)



**Judith Bernal-Ramírez**

Tecnológico de Monterrey

14 PUBLICATIONS 38 CITATIONS

[SEE PROFILE](#)



**Omar Lozano**

Tecnológico de Monterrey

50 PUBLICATIONS 249 CITATIONS

[SEE PROFILE](#)



**Yuriana Oropeza-Almazán**

Rush University Medical Center

18 PUBLICATIONS 116 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



Physiological role of irisin [View project](#)



Synthesis of an organic/inorganic hybrids nanocomposite reinforced with graphene oxide and evaluation of its protective properties against the metal corrosion [View project](#)

**Silica nanoparticles induce cardiotoxicity interfering with energetic status and Ca<sup>2+</sup> handling in adult rat cardiomyocytes**

Carlos Enrique Guerrero-Beltrán<sup>1,2</sup>, Judith Bernal-Ramírez<sup>1, ^</sup>, Omar Lozano<sup>1,3, ^</sup>, Yuriana Oropeza-Almazán<sup>1</sup>, Elena C. Castillo<sup>1</sup>, Jesús Roberto Garza<sup>1</sup>, Noemí García<sup>1,2</sup>, Jorge Vela<sup>1</sup>, Alejandra García-García<sup>5</sup>, Eduardo Ortega<sup>4</sup>, Guillermo Torre-Amione<sup>1,2,6</sup>, Nancy Ornelas-Soto<sup>7</sup>, Gerardo García-Rivas<sup>1,2,\*</sup>

<sup>1</sup>Cátedra de Cardiología y Medicina Vascular, Escuela Nacional de Medicina, Tecnológico de Monterrey. Monterrey, México.

<sup>2</sup>Centro de Investigación Biomédica, Hospital Zambrano-Hellion. Tecnológico de Monterrey. San Pedro Garza-García. México.

<sup>3</sup>Namur Nanosafety Centre (NNC), Namur Research Institute for Life Sciences (NARILIS), Research Centre for the Physics of Matter and Radiation (PMR), University of Namur, Namur, Belgium.

<sup>4</sup>Department of Physics and Astronomy, The University of Texas at San Antonio.

<sup>5</sup>Centro de Investigación en Materiales Avanzados S.C. Unidad Monterrey, Apodaca Nuevo León, México.

<sup>6</sup>Methodist DeBakey Heart & Vascular Center, The Methodist Hospital. Houston, USA.

<sup>7</sup>Laboratorio de Nanotecnología Ambiental, Centro del Agua. Tecnológico de Monterrey. Monterrey, México.

<sup>^</sup> contributed equally to this work

**Running title:** Cardiotoxicity of silica nanoparticles

**Word count of manuscript:** 11,220; **Total Figures:** 11; **Total Tables:** 1

\*Corresponding author

Dr. G. García-Rivas.

23 Hospital Zambrano-Hellion 2do. Piso. Batallón de San Patricio 112. Valle de San Agustín, San Pedro  
24 Garza-García. CP 66278, Nuevo León. México

25 Email: [gdejesus@itesm.mx](mailto:gdejesus@itesm.mx); Phone: +52 (81) 88880472; Fax: +52 (81) 88882223

26

## 27 **Author contributions**

28 Conception and design of research: C.E.G.B. and G.G.R.

29 Performed experiments: C.E.G.B., J.B.R., O.L., Y.O.A., E.C.C., J.R.G., N.G., J.V., E.O., A.G.G., N.O.S.

30 Analyzed data: C.E.G.B., J.B.R., O.L., Y.O.A., E.C.C.,

31 Drafted manuscript: C.E.G.B. and G.G.R.

32 Interpreted results of experiments: C.E.G.B., J.B.R., O.L., E.C.C., G.T.A., G.G.R

33 Prepared figures: J.B.R.

34 Edited and revised manuscript: C.E.G.B., O.L., G.T.A., G.G.R.

35 Approved final version of manuscript: C. E. G.B and G.G.R.

36

## 37 **Abstract**

38 Recent evidence has shown that nanoparticles that have been used to improve or create new  
39 functional properties for common products may pose potential risks to human health. Silicon dioxide  
40 (SiO<sub>2</sub>) has emerged as a promising therapy vector for the heart. However, its potential toxicity and  
41 mechanisms of damage remain poorly understood. This study provides the first exploration of SiO<sub>2</sub>-  
42 induced toxicity in cultured cardiomyocytes exposed to 7 nm or 670 nm SiO<sub>2</sub> particles. We evaluated  
43 the mechanism of cell death in isolated adult cardiomyocytes exposed to 24 h incubation. The SiO<sub>2</sub> cell-  
44 membrane association and internalization were analyzed. SiO<sub>2</sub> showed a dose-dependent cytotoxic

effect with a half-maximal inhibitory concentration for the 7 nm ( $99.5 \pm 12.4 \mu\text{g/ml}$ ) and 670 nm ( $>1500 \mu\text{g/ml}$ ) particles, which indicates size-dependent toxicity. We evaluated cardiomyocyte shortening and intracellular  $\text{Ca}^{2+}$  handling, which showed impaired contractility and intracellular  $\text{Ca}^{2+}$  transient amplitude during  $\beta$ -adrenergic stimulation in  $\text{SiO}_2$  treatment. The time to 50%  $\text{Ca}^{2+}$  decay increased 39%, and the  $\text{Ca}^{2+}$  spark frequency and amplitude decreased by 35% and 21%, respectively, which suggest a reduction in sarcoplasmic reticulum  $\text{Ca}^{2+}$ -ATPase (SERCA) activity. Moreover,  $\text{SiO}_2$  treatment depolarized the mitochondrial membrane potential and decreased ATP production by 55%. Significant glutathione depletion and  $\text{H}_2\text{O}_2$  generation were also observed. These data indicate that  $\text{SiO}_2$  increases oxidative stress, which leads to mitochondrial dysfunction and low energy status; these underlie reduced SERCA activity, shortened  $\text{Ca}^{2+}$  release, and reduced cell shortening. This mechanism of  $\text{SiO}_2$  cardiotoxicity potentially plays an important role in the pathophysiology mechanism of heart failure, arrhythmias, and sudden death.

**Keywords:** Cardiomyocyte; silicon dioxide; nanoparticle; toxicity;  $\text{Ca}^{2+}$

## **New & Noteworthy**

Silica particles are used as novel nanotechnology-based vehicles for diagnostics and therapeutics for the heart. However, their potential hazardous effects remain unknown. Here, the cardiotoxicity of silica nanoparticles in rat myocytes has been described for the first time, showing an impairment of mitochondrial function that interfered directly with  $\text{Ca}^{2+}$  handling.

## **Introduction**

The technological advances of the 20th century have been the most powerful and fastest phenomena in human history. From the largest to the smallest artifacts, newly developed micro/nanomaterials

67 have provided the main base for creating better and more versatile items in almost every area of  
68 knowledge. In this regard, nanotechnology, as we know it in the 21st century, is gaining enormous  
69 acceptance in the electronic, manufacturing, agriculture, consumer-product, and food-additive  
70 industries as well as, more recently, the biotechnological and biomedical fields. Nanomaterials, such as  
71 titania (titanium dioxide) and silica (silicon dioxide,  $\text{SiO}_2$ ), are used to improve and create new  
72 functional properties for common products (51). While nanomaterials based on biomaterials like  
73 polymers, such as poly (lactic-co-glycolic acid) (PGLA) or hydrogels, are considered of low toxicity,  
74 recent evidence has shown that some nanoparticles, such as metal, metal oxides (e.g., silica and  
75 titania), and carbon nanotubes, may pose potential risks to the environment, the food chain, and  
76 human health (35). Several studies have shown that nanoparticles can penetrate the body by different  
77 routes, including the skin, respiratory system, and gastrointestinal tract. In normal conditions, the  
78 inhalation of  $\text{SiO}_2$  is likely the major route by which nanoparticles enter the body, and defective  
79 particle clearance in the airways increases the chance of particles translocating to different organs,  
80 including the heart, lungs, and kidneys (1, 45). Moreover, novel clinical diagnostic protocols and  
81 therapeutic drug treatments allow biological systems to undergo major and extended nano- and  
82 microparticle exposure, which can lead to an inflammatory response, fibrosis, oxidative stress, and cell  
83 death (15). Nano- and micro- $\text{SiO}_2$  particles have drawn a lot of attention in the biomedical field.  
84 Currently, different sizes of  $\text{SiO}_2$  particles are being used in the clinical setting (23). Silica's usefulness as  
85 a biomedical tool has led to focused use in relation to human diagnostic, imaging, and labeling and in  
86 new targeting systems, which allows these nano- and micromaterials to interact directly with the body,  
87 leading to increased concentrations in the bloodstream and higher organ accumulation. In recent  
88 years,  $\text{SiO}_2$  nano- and microparticles have been used extensively due to their chemical properties and

the capacity to manipulate their surface for different biomedical purposes, including for imaging and for therapeutic vehicles (5, 42, 50). However, while silicon-based particles have been considered to be of low toxicity and safe for use as a therapeutic vehicle (40), recent studies have shown evidence of toxicity, though this toxicity depends on a variety of factors, including the composition, differential toxicity among cell types, and—remarkably—particle size (13, 34, 38, 45). In particular, nanoscale particles (<100 nm) are a controversial topic of debate, and the related research conclusions lack consistency. For instance, *in vitro* and *in vivo* effects exerted by SiO<sub>2</sub> particles have recently been studied at the cardiovascular level, which showed cytotoxicity related to induced oxidative stress (10). Acute *in vivo* SiO<sub>2</sub> exposure also leads to an inflammatory response and endothelial dysfunction, which are strongly related to oxidative stress production and to impairments in myocardial antioxidant enzymes (8). Chronic exposure to SiO<sub>2</sub> particles has also been associated with alterations to different molecular mechanisms related to angiogenesis, heart formation and development, and pericardial edema and bradycardia, which can lead to cardiovascular diseases (10). More recently, microarray analysis showed that SiO<sub>2</sub> cardiotoxicity in a zebrafish model was related to oxidative stress and neutrophil-mediated cardiac inflammation (9). However, the mechanisms involved in SiO<sub>2</sub>-induced toxicity in mammalian heart cells are still unknown.

In this study, we explored, for the first time, SiO<sub>2</sub>-induced toxicity and impaired contractility and calcium handling in isolated adult cardiomyocytes exposed to 24 h incubation with two different sizes of SiO<sub>2</sub> particles: 7 nm AEROSIL<sup>®</sup> 380 Fumed Silica, which will be referred to henceforth as nano-SiO<sub>2</sub>, and 670 nm particles synthesized by our group, which will be referred to henceforth as micro-SiO<sub>2</sub>. We explored the mechanism of cell death caused by nano- and micro-SiO<sub>2</sub> at their half-maximal inhibitory concentration (IC<sub>50</sub>) and related these effects to the phenomenon of SiO<sub>2</sub> particle association with

membrane and cellular uptake. Using confocal microscopy, we evaluated cardiomyocyte shortening and intracellular  $\text{Ca}^{2+}$  handling. In addition, we measured the mitochondrial membrane potential, oxidative stress, and ATP content to determine whether  $\text{SiO}_2$  particles induced mitochondrial dysfunction and whether impairment of bioenergetics contributed to  $\text{SiO}_2$ -induced cardiac dysfunction.

## **Materials and methods**

### **Chemicals**

All reagents were obtained from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO) unless otherwise stated.

### **Synthesis of Micro- $\text{SiO}_2$**

The 670nm  $\text{SiO}_2$  particles were synthesized in accordance with the Stöber method (49). Briefly, a mix of 85 % of ethanol, 3.6 % of concentrated ammonium hydroxide solution and 11.5 % (v/v) of ultrapure water was stirred. Separately, a solution was prepared with 30.2 % of tetraethyl orthosilicate (TEOS), 13.2 % of (3-Aminopropyl) triethoxysilane (APTES) and 56.6 % (v/v) of ethanol. This second solution was added slowly to the first one and the mixture was magnetically stirred for 12 h. The resulting colloidal suspension was centrifuged and the precipitate was rinsed with pure ethanol, at least, three times. The solid was then dried in a muffle at 70 °C for 24 h. For the preparation of fluorescent silica spheres (F-Micro- $\text{SiO}_2$ ), dried Micro- $\text{SiO}_2$  spheres obtained of the aforementioned procedure, were subsequently calcined at 400 °C for 2 h. These calcined particles were then washed three times with ethanol in an ultrasonic bath. The fluorescence is attributed to the introduction of carbon and oxygen defects in the silica network after the calcination of APTES (20).

### **Nano- $\text{SiO}_2$ and Micro- $\text{SiO}_2$ characterization**

Nano- $\text{SiO}_2$  (Degussa Co., Parsippany, NJ, US), Micro- $\text{SiO}_2$  and F-Micro- $\text{SiO}_2$  were characterized by a field-emission gun scanning electron microscope (FEG-SEM, model 200 Nova NanoSEM FEI Company).

The measurements were performed under low vacuum conditions, with a Helix detector and a 10-18 kV electron beam. Zeta potential and size measurements using dynamic light scattering (DLS) were performed on a Malvern Zetasizer Nano ZS90 (Malvern Instruments Ltd., Malvern, UK). Briefly, Nano- and Micro-SiO<sub>2</sub> were suspended in ultrapure water, Tyrode, M-199 and M-199 + bovine serum albumin (BSA) (5%) solutions and were irradiated with a red laser (HeNe laser, wavelength  $\lambda = 632.8$  nm) and the intensity fluctuations of the scattered light (detected at a backscattering angle of 173°) were analyzed to obtain an autocorrelation function. The software (DTS v5.03) provided both the mean hydrodynamic diameter and polydispersity index, using the method of cumulants (according to the international standard ISO 13321:19963) and a size distribution using a regularization scheme by intensity, volume, and number. Crystalline structure was determined by X-ray diffraction (XRD) on a Panalytical Empyrean diffractometer (PANalytical Inc., Westborough MA, US).

#### **Cardiomyocytes isolation**

All the studies were performed in accordance with the animal care guidelines of the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). All procedures were approved by the institutional animal use and care committee (protocol number 2011-Re-017). Rat ventricular myocytes were isolated by collagenase II digestion of perfused hearts (14). Briefly, male Wistar rats weighing 250-300 g were used to isolate cardiac cells. Animals were heparinized and anesthetized with pentobarbital (1000 U/kg and 100 mg/kg, i.p. respectively) before removal and hanging the heart. Hearts were mounted on a Langendorff apparatus and then perfused with Tyrode medium (TM), in mM: 128 NaCl, 0.4 NaH<sub>2</sub>PO<sub>4</sub>, 6 glucose, 5.4 KCl, 0.5 MgCl-6H<sub>2</sub>O, 5 creatinine, 5 taurine and 25 HEPES, pH 7.4 at 37 °C., for 5 min and digested by 0.1% collagenase type II (Worthington Biochemical, Lakewood, NJ) dissolved in TM for 15 min. Ventricles



were dissected and cells mechanically disaggregated. Cardiomyocytes were washed in crescent concentrations of calcium (0.25, 0.5, 1 and 1.5 mM) plus 0.1% albumin contained in the TM. Intact cardiomyocytes were cultured in M-199 medium supplemented with (in mM): 5 taurine, 5 creatine, 2 L-carnitine, 2.5 sodium pyruvate, penicillin (100 U/ml) and streptomycin (100 µg/ml) on a laminin-coated culture dishes at a density of  $1 \times 10^4$  viable cells per  $\text{cm}^2$ . Cells were incubated at 37 °C in 95 % air and 5 %  $\text{CO}_2$  for 2 h prior to all experiments.

#### **Determination of Nano-SiO<sub>2</sub> and Micro-SiO<sub>2</sub> cytotoxicity and cell death mechanisms**

To determine SiO<sub>2</sub> cytotoxicity, varying concentrations of Nano- and Micro-SiO<sub>2</sub>, were added to culture media and the incubation was continued for 24 hours. At the end of the incubation period, cytotoxicity of SiO<sub>2</sub> was determined using the Alamar Blue viability test (Life Technologies, Carlsbad, CA, US). The IC<sub>50</sub> was calculated using Origin software (Northampton, MA, US). Necrosis and apoptosis were measured with Ghost Dye Red 780 and Annexin V-PE-Cy7- stained cells using a BD FACSCantoII flow cytometer (BD Biosciences, Heidelberg, Germany). Cells were stained according to the manufacturer's instructions. Briefly 1 µL of Ghost Dye (Tonbo Bioscience, San Diego, CA) solution was added in 1 mL of TM and incubate for 30 min, washed and resuspended in 300 µL with 5 µL of fluorochrome-conjugated Annexin-V-PE-Cy7 (eBioscience, San Diego, CA) by 10 min at room temperature. Finally cells were washed and fixed using 4% paraformaldehyde by 20 min. Following incubation; cell monolayers were washed twice with TM and detached from the culture plate by scrapping. In total 10,000 cells were analyzed per measurement in TM solution and data was analyzed using FlowJo 8.8.6 software (Treestar Inc, Ashland, US). The release of cytoplasmic lactate dehydrogenase (LDH), as a marker of cell integrity and necrosis, was determined enzymatically followed the interconversion of pyruvate and lactate and with concomitant oxidation of NADH to NAD<sup>+</sup> followed by using spectrophotometry at 340 nm. Values

were adjusted to an LDH calibration curve. The activity of caspases 3 and 7, to assess SiO<sub>2</sub>-induced apoptosis, was measured in cell pellets using the Apo-ONE fluorescent substrate (Promega, Madison, WI, USA).

#### **Characterization of Nano-SiO<sub>2</sub> and Micro-SiO<sub>2</sub> in the cardiomyocyte**

In order to assess the interaction between cardiomyocytes membrane and SiO<sub>2</sub> particles, a 24 hours cell incubation with Nano- and Micro-SiO<sub>2</sub> was analyzed by FEG-SEM. Samples were prepared by seeding cardiomyocytes on to 5×7 mm silicon chips specimen supports (Ted Pella, Redding, CA, USA). Samples were fixed with 2.5 % glutaraldehyde, in PBS buffer (Electron Microscopy Sciences, Hatfield, PA, USA) for 20 min, then dehydrated in increasing concentrations of ethanol for 10 min. Specimens were mounted on SEM stubs (Ted Pella, Redding, CA, USA) using conductive adhesive tape (Ted Pella, Redding, CA, USA) and coated with a gold thin film. FEG-SEM surface images were acquired at different magnifications under high vacuum, at 15.00 kV, spot size 3.0, using a Nova NanoSEM 200 (FEI, Hillsboro, OR, US). The energy-dispersive X-ray spectroscopy (EDS) analysis was performed with an Oxford Instruments analyzer and was performed at 15 kV. In addition to surface images, transversal cuts were done on random cardiomyocytes by Focused Ion Beam, and EDS was performed to assess the intracellular location of the SiO<sub>2</sub> particles using a Zeiss Crossbeam 340, using 30kV for the FIB and 12 kV for the SEM. Ten individual cells from each treatment were selected randomly for imaging and EDS analysis.

Particle-induced X-ray emission (PIXE) was used to quantify the total amount of silica present in the cardiomyocytes. This technique has been used recently for nanomaterial quantification in complex matrices (25). A 2.5 MeV proton beam was used to irradiate the cells with currents < 1 nA to reduce sample damage. The cardiomyocytes were incubated with Nano- and Micro-SiO<sub>2</sub> at its IC<sub>50</sub> with

different end time points (0, 1, 12 and 24 h). After each incubation time, cells were: 1) washed with M-199 to remove free particles, 2) detached from the culture plate and 3) centrifuged at 500 rpm through a 250 mM sucrose solution to separate non-internalized and non-adhered silica particles as well as dead cardiomyocytes from the intact cells. The pellet (alive cells) was resuspended in 200  $\mu$ L of MilliQ H<sub>2</sub>O, finally transported sequentially into truncated sample holders and removing the aqueous media following as previously reported (26). Data analysis was done with the GUPIXWIN software (7).

#### **Intracellular localization of F-Micro-SiO<sub>2</sub> by confocal microscopy examination**

To determine the intracellular localization of F-Micro-SiO<sub>2</sub>, cardiomyocytes were seeded into laminin-covered glass coverslips. Cells were incubated with F-Micro-SiO<sub>2</sub> for 24 hours, followed by fixation and staining of cellular structures. Briefly, after SiO<sub>2</sub> incubation, cells were fixed using 4% paraformaldehyde in PBS buffer for 20 min. Immunofluorescence staining was performed by cell permeabilization with 0.1% Triton-X 100 (Thermo Fisher Scientific, Waltham, MA, US) in PBS for 3 min. Cells were rinsed three times in PBS and a blocking step with 1 % bovine serum in PBS was performed for 10 min. Actin filaments were stained with 0.5 unit/ $\mu$ L of Alexa Fluor 568-conjugated phalloidin (Life Technologies, Grand Island, NY, USA) for 20 min at room temperature. Glass coverslips were rinsed with PBS and mounted using vectashield mounting media (Vector laboratories, Burlingame, CA, USA). Samples were imaged using a Leica TCS SP5 confocal microscope equipped with a D-apochromatic 63X, 1.2 NA, oil objective (Leica Microsystems, Wetzlar, Germany). To assess cellular internalization of F-Micro-SiO<sub>2</sub>, a stack of 2D images, with a focal plane thickness of 1  $\mu$ m, were collected every 1  $\mu$ m along z-axis using an excitation (*ex*) and emission (*em*) of 488 nm and 500-700 nm respectively. For the representative images to assess cellular internalization of F-Micro-SiO<sub>2</sub>, wavelengths of an *ex* of 488 nm and 543 nm, and *em* of 500-600 nm and 620-720 nm, for F-Micro-SiO<sub>2</sub> and cytoskeleton were used

respectively. The tridimensional reconstructions were made from z-stacks with a focal plane thickness of 2  $\mu\text{m}$ , using the 3D viewer plugin from ImageJ (NIH, Bethesda, US).

### **Ca<sup>2+</sup> handling and cell shortening in intact cardiomyocytes**

The Ca<sup>2+</sup> transients, Ca<sup>2+</sup> sparks, and cell shortening parameters were measured as previously described (29, 53). 24 hours cultured cardiomyocytes on laminin-covered glass coverslips, with Nano- and Micro-SiO<sub>2</sub> at its IC<sub>50</sub>, were incubated in TM with Fluo-4 AM or Fluo-3 AM (Life Technologies, Carlsbad, CA, US) to evaluate Ca<sup>2+</sup> handling, and cell shortening. Afterwards, the cells were washed with a fluorophore-free solution. Loaded cells were mounted in a superfusion chamber. All fluorescence measurements were acquired with a Leica TCS SP5 confocal microscope equipped with a D-apochromatic 63X, 1.2 NA, oil objective (Leica Microsystems, Wetzlar, Germany). Line scan images were recorded along the longitudinal axis of the cell at 400 Hz using an Argon laser to excite the fluorophore at 488 nm and its emission was collected at 500-600 nm. For cell shortening, a pinhole optimized for a 4  $\mu\text{m}$  section thickness in the focal plane was used, while a 1  $\mu\text{m}$  section thickness was used for Ca<sup>2+</sup> signaling. Cell shortening was evaluated under field stimulation at 0.5, 1 and 2 Hz (MYP100 MyoPacer Field Stimulator; Ion-Optix, Milton, MA). For Ca<sup>2+</sup> transient and Ca<sup>2+</sup> sparks the cells were field stimulated by 3 to 5 electric pulses at 1 Hz to attain steady state sarcoplasmic reticulum (SR) Ca<sup>2+</sup> content. The Ca<sup>2+</sup> signaling under  $\beta$ -adrenergic stimulation was evaluated by perfusion of isoprenaline (ISO) at 100 nM and the records were taken after 10 min of exposition. For SR Ca<sup>2+</sup> content, the cells were field stimulated at 1 Hz before a rapid caffeine application at 10 mM. Fluorescence data were normalized as  $\Delta F/F_0$ , where F is fluorescence intensity and F<sub>0</sub> is average fluorescence at rest.

### **Bioenergetic status measurements**

243 Mitochondrial membrane potential ( $\Delta\psi$ ) was evaluated in cultured cardiomyocytes by confocal  
244 microscopy using a Leica TCS SP5 confocal microscope equipped with a D-apochromatic 63X, 1.2 NA, oil  
245 objective (Leica Microsystems, Wetzlar, Germany). Cardiomyocytes on laminin-coated coverslips were  
246 treated with Nano-SiO<sub>2</sub> for 24 hours, washed with TM to remove particles and loaded with 300 nM  
247 tetramethylrhodamine ethyl ester perchlorate (TMRE, Thermo Fisher Scientific, Waltham, MA, US)  
248 during 30 minutes at room temperature and darkness. TMRE accumulates in metabolically active  
249 mitochondria producing a fluorescence that is proportional to  $\Delta\psi$  (44). Afterward, the cells were rinsed  
250 with fluorophore-free TM and placed in a recording chamber. TMRE signal was measured with an *ex* at  
251 543 nm and an *em* to 560-700 using oil immersion 40X objective. To evaluate the  $\Delta\psi$ , records were  
252 taken after field stimulation at 1 Hz. The 2-dimensional images were acquired with Leica LAS AF version  
253 2.7 format at 400 Hz with 512 x 512 image size and a focal plane thickness of 1  $\mu$ m. The total  
254 fluorescence from the 2-D images was evaluated and plotted as a percentage of relative fluorescence,  
255 being control group the 100%. ATP content was measured in control group (CT) cardiomyocytes as well  
256 as those treated with Nano-SiO<sub>2</sub> at its IC<sub>50</sub>, after a 24 h exposure, using the CellTiter-Glo Luminescent  
257 Assay (Promega, Madison, US).

#### 258 **Oxidative stress markers**

259 A change in the concentration of H<sub>2</sub>O<sub>2</sub> in the medium was detected by fluorescence of the oxidized  
260 Amplex Red (Life Technologies, Carlsbad, CA, US) using wavelengths of *ex* at 550 nm and *em* at 585 nm.  
261 The response of Amplex Red to H<sub>2</sub>O<sub>2</sub> was calibrated by sequential additions of known amounts of H<sub>2</sub>O<sub>2</sub>  
262 from 100 to 1000 pmol/min. Glutathione (GSH) was measured as previously described (39). Briefly,  
263 cells were dissolved in medium containing (in mM): 50 KH<sub>2</sub>PO<sub>4</sub>, pH 7.5 with the addition of 0.2% Tx-  
264 100, 1 PMSF and 0.6 % sulfosalicylic acid for 10 min at 4 °C and centrifuged at 8000 rpm for 10 min.

Protein concentration was measured by Lowry method. 30  $\mu\text{g}$  of protein were incubated in a medium that contained (in mM): 50  $\text{KH}_2\text{PO}_4$ , 1 EDTA, pH 7.5 with the addition of GSH reductase 10 U/ml, 0.1 DTNB and 2 NADPH. The reduction of DTNB was followed at 412 nm and quantified with extinction coefficient ( $13.6 \text{ M}^{-1}\text{cm}^{-1}$ ).

### Statistical analyses

Data were analyzed by ANOVA followed by Dunnett's multiple comparisons tests using Graph Pad InStat (Graph Pad Software Inc., San Diego, US) or by student t-test, as indicate. Data were expressed as mean  $\pm$  S.E.M. A p-value  $<0.05$  was considered statistically significant.

## Results

### Characterization of $\text{SiO}_2$ particles

The characterizations of the nano- and micro- $\text{SiO}_2$  particles are presented in Figure 1. The field-emission gun scanning electron microscope (FEG-SEM) images show that the micro- $\text{SiO}_2$  had a spherical shape and exhibited dispersibility (Figure 1A). The size distribution shown by FEG-SEM analysis had an average diameter of  $670 \pm 32 \text{ nm}$  (insert, Figure 1A), while the average diameter of nano- $\text{SiO}_2$  was 7 nm according to the manufacturer's technical sheet. Analysis of the crystalline structure using XRD showed that the nano- and micro- $\text{SiO}_2$  particles presented an amorphous structure (Figure 1B). The hydrodynamic diameters (Figure 1C) of the nano- and micro- $\text{SiO}_2$  particles in ultrapure water were  $91 \pm 22 \text{ nm}$  and  $712 \pm 212 \text{ nm}$ , respectively. The zeta potentials of the nano- and micro- $\text{SiO}_2$  particles (Figure 1D) were  $-27.1 \pm 4.4 \text{ mV}$  and  $-14.4 \pm 5.48 \text{ mV}$ , respectively. Hydrodynamic diameters and zeta potentials were also measured in Tyrode, M-199, and M-199 + BSA solutions (Table 1). In addition, EDS analysis showed that the purity of the silica particles was higher than 95%, and no

287 traces of other metals were detected in the particle suspensions (data not shown).

#### 288 **Dose- and time-dependent cytotoxicity of nano- and micro-SiO<sub>2</sub> particles**

289 To assess the effects of SiO<sub>2</sub> on cardiomyocyte viability, adult-rat ventricular myocytes were cultured  
290 with different concentrations of nano- and micro-SiO<sub>2</sub> particles, and cell death was examined after 24 h  
291 of treatment. As shown in Figure 2A, nano- and micro-SiO<sub>2</sub> induced significant cytotoxic effects in a  
292 dose-dependent manner, with IC<sub>50</sub> values of  $99.5 \pm 12.4$  µg/ml and >1500 µg/ml, respectively, which  
293 indicates that nano-SiO<sub>2</sub> has a 15-fold higher toxicity than micro-SiO<sub>2</sub>. Indeed, when the cardiomyocytes  
294 were cultured in the presence of nano- and micro-SiO<sub>2</sub> at the IC<sub>50</sub> of nano-SiO<sub>2</sub>, only nano-SiO<sub>2</sub>-induced  
295 cell death occurred as a result of the necrotic pathway. No evidence of apoptosis was observed in any  
296 case, as shown by the lack of single positive Annexin V cells (Figure 2B-C) and the lack of caspase 3/7  
297 activity (data not shown). In addition, necrosis induction also occurred faster with nano-SiO<sub>2</sub> than with  
298 micro-SiO<sub>2</sub> as shown in Figure 2D by the lactate dehydrogenase (LDH) leakage. Nano-SiO<sub>2</sub> promoted  
299 cardiomyocyte necrosis in the first 3 h of incubation, while micro-SiO<sub>2</sub> only led to significant LDH  
300 leakage after 12 h at their corresponding IC<sub>50</sub> values.

#### 301 **SiO<sub>2</sub> particles associate with the cellular membrane and internalize in the cell**

302 In order to relate cellular death to particle membrane association or to the potential internalization of  
303 the SiO<sub>2</sub> particles, we analyzed the association of single or agglomerates/aggregates of nano- and  
304 micro-SiO<sub>2</sub> to the cardiomyocytes' cellular membranes, as shown in Figure 3A-B. The FEG-SEM images  
305 show the association of the SiO<sub>2</sub> particles with the cell membrane 24 h after administration in the  
306 cultured adult-rat cardiomyocytes at 37°C (Figure 3A-B). Figure 4 depicts the surface of the  
307 cardiomyocytes using EDS, which shows that the nano- and micro-SiO<sub>2</sub> particles have individual and

308 agglomerate/aggregate associations with the cellular membrane with respect to the four EDS images  
309 of the elemental maps for carbon, sodium, silicon, and oxygen. Transversal cuts in the cardiomyocytes  
310 with nano- or micro-SiO<sub>2</sub> (Figure 3C-E) showed that the particles could internalize in the  
311 cardiomyocytes after 24 h incubation. Figure 3F shows the SiO<sub>2</sub> content quantified by particle-induced  
312 X-ray emission (PIXE) in the cardiomyocytes as a function of time. A time-dependent increase was  
313 observed in SiO<sub>2</sub> in the cardiomyocytes treated with nano- and micro-SiO<sub>2</sub> particles, suggesting an  
314 association/internalization of the silica particles in the cardiomyocytes. Furthermore, EDS analysis in  
315 the transversal cut in the cardiomyocytes indicates that the SiO<sub>2</sub> signal is higher in nano-SiO<sub>2</sub> versus  
316 micro-SiO<sub>2</sub> particles, which suggests that smaller SiO<sub>2</sub> particles are more prone to cellular  
317 internalization in cardiomyocytes. As shown in Figure 3G, we explored, by confocal microscopy, the  
318 internalization of micro-SiO<sub>2</sub> after 24 h incubation, and we analyzed the confocal z-stack acquisitions.  
319 For this purpose, we synthesized a micro-SiO<sub>2</sub> particle with fluorescent properties (F-micro-SiO<sub>2</sub>) that  
320 had a similar size, morphology, dispensability, and zeta potential as micro-SiO<sub>2</sub> (Table 1). Using this  
321 approach, we confirmed the presence of multiple single and agglomerate/aggregate F-micro-SiO<sub>2</sub> at  
322 different subcellular levels using a tridimensional reconstruction captured from cardiomyocytes,  
323 thereby confirming the intracellular localization of SiO<sub>2</sub> particles (Figure 3G, Video 1). We also  
324 visualized the internalization of the F-micro-SiO<sub>2</sub> through confocal z-stack analysis, which confirmed  
325 the presence of particles (shown as bright spheres) near the nuclei area (shown as dark ovals) (Figure  
326 3G). Figure 5 shows a semi-quantitative analysis wherein the total fluorescence in a z-stack was  
327 evaluated to determine the internalization of the F-micro-SiO<sub>2</sub> in intact cardiomyocytes exposed to  
328 different concentrations of particles during 24 h incubation. F-micro-SiO<sub>2</sub> exhibited dose-dependence  
329 at low concentrations (Figure 5A) and was able to reach a saturating concentration without promoting



significant cellular death (data not shown), which is similar to micro-SiO<sub>2</sub> at the same concentration (Figure 2A), and we showed that cardiomyocytes treated with 150 µg/ml of F-micro-SiO<sub>2</sub> preserved their normal morphology (Figure 5B). At the maximum evaluated concentration of 150 µg/ml, we observed a two-fold increase in fluorescence; the  $1 \pm 0.17$ -fold fluorescence presented in the untreated (CT) group increased to  $2.02 \pm 0.41$ -fold in the F-micro-SiO<sub>2</sub>-treated group (Figure 5B).

### **SiO<sub>2</sub> treatment induced a reduction in cell shortening, decreased SERCA activity, and impaired $\beta$ -adrenergic stimulation**

Cardiomyocyte sarcomere shortening (Figure 6) following nano- and micro-SiO<sub>2</sub> treatment reduced by 34% and 36%, respectively, compared to the CT group. This impairment in cell shortening was maintained at 0.5 and 2 Hz. However, no difference was evident between the nano- and micro-SiO<sub>2</sub> groups. For the purpose of exploring the mechanism of this impairment, we chose to work with nano-SiO<sub>2</sub> particles at 100 µg/ml in order to match the physiological conditions of airways and to avoid high range concentrations (IC<sub>50</sub> values of >1500 µg/ml for micro-SiO<sub>2</sub>) that could not be detected *in vivo* after a short exposure.

Generally, the changes in cardiomyocyte Ca<sup>2+</sup> handling followed the time course of the changes in contractility. In this sense, Figure 7A-B shows a representative recording of Ca<sup>2+</sup> transients evoked by field stimulation for the control and nano-SiO<sub>2</sub>-treated cells. Figure 7C shows the pooled data of the change in the Ca<sup>2+</sup> transient peak amplitude upon physiological  $\beta$ -adrenergic stimulation ISO in both cell treatments. We found that under basal conditions, the peak Ca<sup>2+</sup> transient amplitude was similar in the SiO<sub>2</sub>-treated and CT cells ( $6.03 \pm 0.27 \Delta F/F_0$  CT vs.  $6.72 \pm 0.37 \Delta F/F_0$  nano-SiO<sub>2</sub>). However, after 10

350 min of continuous  $\beta$ -adrenergic stimulation, the  $\text{Ca}^{2+}$  transient amplitude increased to only  $7.95 \pm 0.72$   
 351 in the nano-SiO<sub>2</sub>-treated cells, while the control group increased to  $9.13 \pm 0.59$  ( $P < 0.05$ ).

352 For relaxation, the released  $\text{Ca}^{2+}$  must be removed from the cytosol; SERCA and the sarcolemmal  
 353  $\text{Na}^+/\text{Ca}^{2+}$  exchanger perform this activity. In this context, the  $\text{Ca}^{2+}$  transient time to 50% decay ( $T_{50\%}$ )  
 354 provides an index of the combined activity of the  $\text{Ca}^{2+}$  removal systems; however, the SERCA activity  
 355 underlies more than 90% of  $\text{Ca}^{2+}$  removal (4). Figure 7D shows the  $\text{Ca}^{2+}$  transient  $T_{50\%}$  plotted under  
 356 basal conditions and as a function of time during ISO perfusion. Under basal conditions, the  $T_{50\%}$  of the  
 357 nano-SiO<sub>2</sub>-treated cells was  $331 \pm 23$  ms, while that of the CT cells was  $239 \pm 11$  ms ( $P < 0.05$ ). In both  
 358 cases, there was an increase in the cytosolic  $\text{Ca}^{2+}$  removal rate after adrenergic stimulation; however,  
 359 there was still a difference between the CT and nano-SiO<sub>2</sub>-treated cells ( $183 \pm 7$  and  $233 \pm 14$  ms,  
 360 respectively;  $P < 0.05$ ). This result suggests impairment in SERCA activity.

361 Because alterations in  $\text{Ca}^{2+}$  handling in other pathological settings are also reflected at the level of  
 362 diastolic  $\text{Ca}^{2+}$ , we measured whether the spontaneous  $\text{Ca}^{2+}$  sparks were altered in the SiO<sub>2</sub>-treated  
 363 cardiomyocytes. Figure 8A shows the typical  $\text{Ca}^{2+}$  spark reconstruction in the CT (left) and nano-SiO<sub>2</sub>-  
 364 treated cardiomyocytes (right). Calcium spark analysis revealed a significant decrease in frequency in  
 365 the nano-SiO<sub>2</sub> group ( $1.81 \pm 0.28$  sparks/100  $\mu\text{m}/\text{sec}$  nano-SiO<sub>2</sub>) compared with the CT group ( $2.79 \pm$   
 366  $0.26$  sparks/100  $\mu\text{m}/\text{sec}$  CT) ( $P < 0.05$ ) (Figure 8B) and a significant decrease in amplitude ( $0.82 \pm 0.02$   
 367  $F/F_0$  CT vs.  $0.65 \pm 0.03$   $F/F_0$  nano-SiO<sub>2</sub>;  $P < 0.05$ ) (Figure 8C), which might indicate reduced SR calcium  
 368 content. We estimated a steady-state SR  $\text{Ca}^{2+}$  content by the cytosolic peak of the caffeine-evoked  $\text{Ca}^{2+}$   
 369 release in the CT and SiO<sub>2</sub>-treated cells. Figures 9A-B shows representative confocal images of caffeine-  
 370 evoked SR  $\text{Ca}^{2+}$  release in the control and nano-SiO<sub>2</sub> treated cells, respectively. Pooled data of the peak

caffeine-evoked  $\text{Ca}^{2+}$  release is shown in Figure 9C. The nano- $\text{SiO}_2$  cells had a slightly lower SR  $\text{Ca}^{2+}$  content, the difference was not statistically significant under basal conditions ( $5.48 \pm 0.35$  and  $4.59 \pm 0.46$  for CT and nano- $\text{SiO}_2$  treated cells, respectively;  $P < 0.12$ ).

#### **$\text{SiO}_2$ treatment induces a decrease in mitochondrial membrane potential and ATP content**

Efficient  $\text{Ca}^{2+}$  handling, which is necessary for proper contraction and relaxation, depends strongly on the ATP supply in the vicinity of SERCA (11). In this regard, we explored whether  $\text{SiO}_2$  treatment affected the bioenergetics status in nano- $\text{SiO}_2$ -treated cardiomyocytes (Figure 10 A-B). Figure 10C shows a 29.5% decrease in the mitochondrial membrane potential ( $\Delta\psi$ ) with nano- $\text{SiO}_2$  treatment compared to the CT group after 24 h incubation. This finding was strongly related to the ATP content in the cardiomyocytes, as nano- $\text{SiO}_2$  treatment reduced the ATP content by 60% compared to the CT cells (Figure 10D). These findings suggest that the  $\text{SiO}_2$  particles impaired mitochondrial function.

#### **$\text{SiO}_2$ induces ROS production and glutathione depletion**

Modification of the redox state by nano- and microparticles has been reported as one of the main mechanisms of cytotoxicity at the cellular level (35). In this regard, we incubated cardiomyocytes with nano- $\text{SiO}_2$  for 24 h and then measured  $\text{H}_2\text{O}_2$  production and glutathione (GSH) content. Figure 10E shows that the  $\text{SiO}_2$  particles significantly increased  $\text{H}_2\text{O}_2$  production and markedly depleted GSH (Figure 10F) compared to the CT group. Nano- $\text{SiO}_2$  induced a significant reduction in GSH (down to 6.5 nmol/mg) in comparison to the CT group (15.4 nmol/mg), which shows that silica particles exerted a pro-oxidative status on adult-rat cardiomyocytes.

## 392 **Discussion**

393 The purpose of this study was to evaluate, for the first time, the potential cardiotoxicity of SiO<sub>2</sub>  
 394 particles in adult cardiomyocytes and their effects on excitation–contraction coupling. In addition,  
 395 recent results have shown that silicon-based microparticles associate and accumulate in a failing  
 396 myocardium (in contrast to a healthy myocardium) following intravenous administration, and the  
 397 microparticles reach the cardiomyocytes. This finding points to a novel avenue for developing  
 398 nanotechnology-based therapeutics and diagnostics for heart failure and other cardiomyopathies that  
 399 involve endothelial dysfunction and a proinflammatory milieu (40). In addition, there is great interest in  
 400 using these materials therapeutically as vehicles for carrying genes, siRNA, drugs, or peptides, and  
 401 there are promising results (5, 42) due to their physicochemical properties, the capacity of biochemical  
 402 functionality and surface modification to immobilize biomolecules, and the easy preparation of diverse  
 403 particle sizes (nano and micro) with uniform shapes and structures (37).

## 404 **SiO<sub>2</sub> nanoparticle internalization is associated with cardiotoxicity**

405 SiO<sub>2</sub> particles have displayed various cytotoxic effects at the cellular level, which has led to growing  
 406 concern about their safety (15, 33, 35). Importantly, the toxicity of SiO<sub>2</sub> particles might depend on their  
 407 crystalline nature and morphology, but this was not considered as a variable in this work because  
 408 nano- and micro-SiO<sub>2</sub> have a spherical shape and the same crystalline nature. However, one important  
 409 factor for consideration in this work is the particle size (45). It is generally accepted that the smaller the  
 410 particles, the greater the toxicity exerted in biological systems. In our study, we found differential  
 411 cardiotoxicity between nano- and micro-SiO<sub>2</sub>. In agreement with many previous studies (34), nano-SiO<sub>2</sub>  
 412 particles exerted potent cytotoxicity compared with micro-SiO<sub>2</sub> particles at the same concentration  
 413 (e.g., 300 µg/ml). Nano-SiO<sub>2</sub> reduced viability nearly 80%, as compared to 30% for micro-SiO<sub>2</sub>. Our

414 results indicate that nanoparticles are more toxic to adult-rat ventricular myocytes than microparticles.  
415 Consistent with our results, Duan et al. (9), using 70 nm SiO<sub>2</sub> nanoparticles, observed pericardial edema  
416 and cardiac toxicity in zebrafish embryos, which affected heart rhythm. These observations should be  
417 considered when designing new products for medical applications or for novel vehicles for gene/drug  
418 delivery.

419 We previously mentioned our decision to evaluate SiO<sub>2</sub> particle size and stability in ultrapure water  
420 and, more importantly, in culture media (Tyrode, M-199, and M-199 + BSA) in order to know SiO<sub>2</sub>  
421 particle properties where all experiments have been performed. One of the main characteristics of the  
422 DLS technique is that DLS “is a function of the relative refractive indices of the particle or molecule and  
423 the dispersant” (24). In our case, when measurements are made in a culture medium, the molecules  
424 within it scatter light, which causes interference; thus, the data can probably not be gathered with  
425 100% efficiency. However, the changes in the physicochemical properties (particle size distribution and  
426 surface charge) of the SiO<sub>2</sub> particles in the culture media were determined using an incubation  
427 protocol adapted from Monopoli et al. (32) to assess the formation of the hard protein corona around  
428 the particles. The results, as shown in Table 1, effectively indicate that the more complex the media in  
429 which the SiO<sub>2</sub> particles are exposed, the greater the tendency to increase in size; nevertheless, we  
430 showed that their surface charge remained relatively unmodified, as it remained negative for all  
431 samples under all tested conditions. The zeta potential of the nano-SiO<sub>2</sub> was -24.1 mV, while for the  
432 micro-SiO<sub>2</sub> and its fluorescence-modified counterpart it was -14.4 and -33.6 mV, respectively. Overall,  
433 these changes are not significant enough to expect dramatic changes in their interaction with cells,  
434 such as in the internalization effects. It was not until relatively recently that the ζ-potential, which  
435 represents the surface charge of a given set of particles, became relevant as a key factor that

influences processes such as opsonization and internalization. Examples of such dramatic changes were presented by Arvizo et al. (2), who tested these aforementioned key factors in gold nanoparticle-coated polymers that conferred surface charges that were positive, negative, or neutral. They found that particles with a neutral surface charge (i.e., a zeta potential  $< |2|$  mV) had longer circulation times and consequently higher accumulation in tumors. Other studies with cancer cell lines, such as HeLa (18, 30), and endothelial cells (43) found *in vivo* that particles with a positive surface charge had higher internalization rates than negative or neutral particles. For cardiac cells specifically, Miragoli et al. (31) found that exposure in cultured neonatal-rat myocytes to 50 nm-charged polystyrene particles showed contrasting effects based on the type of surface charge: positively charged particles showed higher cytotoxic effects, while negatively charged particles showed lower cytotoxicity but formed 50–250 nm nanopores that induced pro-arrhythmic events.

In this work, we observed differences in the cell-release levels of LDH after 24 h incubation of SiO<sub>2</sub>. As shown in Figure 2C, nano-SiO<sub>2</sub> produced a two-fold increase in activity compared with micro-SiO<sub>2</sub>-treated cells. This difference was made more evident by the fact that SiO<sub>2</sub>-induced necrosis occurred in a time-dependent manner, in accordance with previous reports, and nano-SiO<sub>2</sub> caused LDH leakage in endothelial cells at similar times and doses (10). Figure 2D shows cell-membrane damage as early as in the first three hours of incubation with nano-SiO<sub>2</sub>; this phenomenon is probably due to the size of nano-SiO<sub>2</sub>, which allows it to penetrate faster through the cell membrane, in turn causing an early permeabilization process that has important cytotoxic effects. This cytotoxic effect was also exerted by the micro-SiO<sub>2</sub> as early as the first two hours, but significant LDH release was shown only after 12 hours of incubation. In this scenario, membrane permeabilization and LDH release indicate the

457 beginning of necrosis in SiO<sub>2</sub>-treated cells. Apoptosis cell death was not observed, potentially due to  
458 the reduced energetic metabolites.

459 As observed, micro-SiO<sub>2</sub> exerted a lower cytotoxic effect compared with nano-SiO<sub>2</sub>. To understand this  
460 difference, we developed a hypothesis with two scenarios: 1) micro-SiO<sub>2</sub> does not associate properly  
461 with cardiomyocyte membranes, and 2) the larger particle size of micro-SiO<sub>2</sub> prevents it from  
462 penetrating into cardiomyocytes, thus avoiding membrane disruption and cell damage. Based on this,  
463 we explored the association of SiO<sub>2</sub> particles with cellular membranes. The FEG-SEM micrographs show  
464 that nano- and micro-SiO<sub>2</sub> associated with cells as individuals and agglomerates/aggregates, and there  
465 was evidence of an internalization process and a strong interaction between SiO<sub>2</sub> and cell membranes.  
466 In accordance with this, the quantification by PIXE revealed that there was a concentration of SiO<sub>2</sub> in  
467 the cardiomyocytes,, while no traces of SiO<sub>2</sub> were found in the unexposed cells (CT group). The  
468 concentration increased 3.3- and 4.5-fold for nano- and micro-SiO<sub>2</sub>, respectively. These concentrations  
469 correspond to particles that were either internalized or that adhered to the cardiomyocytes.

470 To explore the second hypothesis, we incubated fluorescent micro-SiO<sub>2</sub> and analyzed its internalization  
471 using confocal microscopy. We confirmed that micro-SiO<sub>2</sub> was localized inside the cardiomyocytes,  
472 following a dose-dependent manner, with some association near the nucleus, an interesting  
473 phenomenon that is widely observed in different phagocytic cellular types (13, 27) but rarely explored  
474 in non-dividing cells. Adult cardiomyocytes, as a non-dividing cell type and with an apparent non-  
475 phagocytic capacity, represent an interesting opportunity to study the biological phenomena of nano-  
476 and microparticle internalization and intracellular trafficking. Our group recently studied the

477 mechanisms for the internalization, trafficking, and perinuclear particle localization of these-  
478 apparently not-quiescent cardiomyocytes (40).

479 **Calcium mishandling is associated with SiO<sub>2</sub> nanoparticle cardiotoxicity**

480 Aberrant Ca<sup>2+</sup> handling is an important contributor to the electrical and contractile dysfunction  
481 associated with cell death. Recently, Gilardino et al. (16) found evidence that, in a neuronal cell line,  
482 SiO<sub>2</sub> nanoparticles induce oscillatory changes in intracellular Ca<sup>2+</sup>. Although Ca<sup>2+</sup> returns to baseline in  
483 about 4 h, these authors suggests that several voltage-dependent Ca<sup>2+</sup> channels on the plasmatic  
484 membrane are responsible for these effects. Our results do not agree with this, as they suggest that  
485 extracellular Ca<sup>2+</sup> transport remains functional between the L-type Ca<sup>2+</sup> channel and SR interaction  
486 because the time to peak of Ca<sup>2+</sup> release remains intact (data not shown). On the other hand, we  
487 observed that the decreased contractility in SiO<sub>2</sub>-treated cardiomyocytes could also be due to  
488 alterations in Ca<sup>2+</sup> signaling. In this regard, we found that the electrically evoked Ca<sup>2+</sup> transients were  
489 blunted with slow decay and were less sensitive to physiological β-adrenergic stimulation during ISO  
490 perfusion. The reduced Ca<sup>2+</sup> transient amplitude could be due to either decreased SR Ca<sup>2+</sup> content or a  
491 decrease in the L-type Ca<sup>2+</sup> channel current density. The general consensus is that there is a modest  
492 change, or no change, in the Ca<sup>2+</sup> current, even in the context of pathologies as profound as heart  
493 failure. However, there is much evidence associated with a state of SR Ca<sup>2+</sup> depletion in pathologies  
494 such as doxorubicin-induced cardiomyopathy (36). Decreased SERCA activity and lower intra-SR Ca<sup>2+</sup>  
495 content in SiO<sub>2</sub>-treated cardiomyocytes might explain the smaller amplitude of Ca<sup>2+</sup> transients and Ca<sup>2+</sup>  
496 sparks. The lower SR Ca<sup>2+</sup> content in SiO<sub>2</sub> nanoparticle-treated cells, as well as the slow rate of Ca<sup>2+</sup>  
497 transient decay, could be explained by different events that can alter the SERCA function, such as low  
498 ATP content, as shown in this work (Figure 10), or a decreased SERCA expression, which was recently



observed in microarrays from zebrafish embryos treated with SiO<sub>2</sub> nanoparticles (9). However, several studies have shown that decreased SERCA activity is not necessarily accompanied by decreased protein expression (55), and it has been pointed out by our group that Ca<sup>2+</sup> signaling alterations may precede the changes in protein expression (24). To explain diminished capacity of SERCA to reload the SR, we should consider the consequences of mitochondrial dysfunction due to the drop in membrane potential and the low ATP content (Figure 10), particularly during high cardiac workloads. A reduced capacity for energy supply (22) and the ineffective removal of the end products of ATP hydrolysis have been observed in heart failure, which leads to a reduction in the phosphorylation potential, which can in turn affect the ATPases involved in Ca<sup>2+</sup> handling (22). SERCA is one of the most energy-demanding, and therefore most sensitive, cardiac enzymes in ATP depletion. Based on this, dysfunctional mitochondria and a lower ATP content could undermine cytosolic Ca<sup>2+</sup> removal by SERCA, decrease contractile strength, and slow muscle relaxation, which we observed in SiO<sub>2</sub>-treated cardiomyocytes. However, while the SR Ca<sup>2+</sup> content was slightly lower in the SiO<sub>2</sub>-treated cells, under basal conditions we found a decrease in the spontaneous Ca<sup>2+</sup> spark amplitude and frequency. Because a steady state SR Ca<sup>2+</sup> content results from the balance between SERCA activity and SR Ca<sup>2+</sup> leakage, the latter reflected spontaneous Ca<sup>2+</sup> sparks and the decrease in SR Ca<sup>2+</sup> leakage might explain the lower SR Ca<sup>2+</sup> content observed in cells treated with SiO<sub>2</sub> nanoparticles; this phenomenon could also be exacerbated and deregulated under continuous β-adrenergic stimulation, as we showed in our electrically evoked Ca<sup>2+</sup> transients under ISO stimulation (Figure 7). Altogether, these findings are in agreement with reports on ventricular dysfunction and ischemic heart disease in which diastolic Ca<sup>2+</sup> release is increased (12, 53).

#### **Mitochondrial dysfunction as a trigger of SiO<sub>2</sub> toxicity**

521 As we mentioned before, in cardiomyocytes the excitation–contraction coupling and metabolic  
522 adaptations are based on the coordination between the mitochondria and SR, which facilitates the ATP  
523 supply for SERCA activity and ensures energy replenishment by  $\text{Ca}^{2+}$  and ADP exchange (14, 52). For  
524 this reason, mitochondrial function is recognized as an important player in regulatory  $\text{Ca}^{2+}$  signaling in  
525 the heart (52). However, the impact of  $\text{SiO}_2$  nanoparticles on energy metabolism and mitochondrial  
526 function is largely unclear. Our findings demonstrate that exposing cardiomyocytes directly to  $\text{SiO}_2$   
527 nanoparticles for 24 h induced mitochondrial membrane depolarization and energy debacle (Figure  
528 10), and even more membrane depolarization and energy debacle after 10 min of continuous  $\beta$ -  
529 adrenergic stimulation under ISO treatment (data not shown).

530 Xue et al. (54) observed  $\text{SiO}_2$  nanoparticle–induced suppression of mitochondrial dehydrogenase  
531 activity and ATP synthesis in hepatocytes. Following *in vitro* exposure, the internalization of  $\text{SiO}_2$   
532 nanoparticles correlates with the disturbance of the mitochondrial structure and the release of  
533 reactive oxygen species (ROS) in hepatocellular carcinoma cells (47). In this context, cardiac  
534 mitochondria allow energy supply–demand matching and regulate the generation of antioxidant  
535 defenses, such as nicotinamide adenine dinucleotide phosphate and GSH (28). However, under the  
536  $\text{Ca}^{2+}$  handling impairment—as observed during  $\text{SiO}_2$  nanoparticle interaction—increased electron  
537 leakage from the electron transport chain, and the subsequent production of ROS and depletion of  
538 antioxidant reserves, has been observed (19). Similar to previous results, it was observed that nano-  
539  $\text{SiO}_2$  incubation induced a significant amount of  $\text{H}_2\text{O}_2$  (a highly toxic type of oxygen-free radical) and a  
540 potent depletion in GSH (a first-line antioxidant defense), which indicates  $\text{SiO}_2$ -induced cytotoxicity  
541 that is at least partially due to an imbalance in the cellular redox status. In this regard, it is possible that  
542 SERCA and/or the ryanodine receptor might be oxidized, as has been described in other works (3), and

543 this could, at least partially, underlie the slow rate of  $\text{Ca}^{2+}$  transient decay and the decrease in the  
544 amplitude and frequency of sparks. An enhanced diastolic  $\text{Ca}^{2+}$  leak may not only contribute to the  
545 decreased SR  $\text{Ca}^{2+}$  content but also increase the risk of delay after depolarization and  $\text{Ca}^{2+}$ -triggered  
546 arrhythmias, as previously observed by Szebeni et al. (48) with lipid-based nanoparticles in a pig model.  
547 A recent study also showed another possible mechanism of cardiotoxicity with metal-oxide  
548 nanoparticles. Savi et al. (41), using nano- $\text{TiO}_2$  particles that had a z-potential similar to that of our  
549 nano- $\text{SiO}_2$  particles but a different crystalline nature (a mixture of anatase and rutile, as compared to  
550 our amorphous  $\text{SiO}_2$ ), observed that nano- $\text{TiO}_2$  particles promoted spontaneous contraction in  
551 cardiomyocytes (an arrhythmia trigger at the cellular level). This effect was related to the slight  
552 depolarization of the resting membrane potential, which consequently reduced the action potential  
553 duration. Then, using an in silico model, they suggested that nano- $\text{TiO}_2$  particles generate transient  
554 nanopores that lead to resting membrane potential instability, possibly due to  $\text{K}^+$  leakage (41).  
555 In this context, our results with nano- $\text{SiO}_2$  particles suggest that there was no change in the action  
556 potential because the kinetics of  $\text{Ca}^{2+}$  release from the sarcoplasmic reticulum were not affected (time  
557 to peak; data not shown) and spontaneous contraction was not observed. However, our experiments  
558 were performed at 24 h, while the  $\text{TiO}_2$  particles were analyzed 1 h after particle addition, so further  
559 experiments on patch-clamped cardiomyocytes with simultaneous measurement of  $\text{Ca}^{2+}$  handling  
560 might help to establish a potential connection between these mechanisms of cardiotoxicity.  
561 Interestingly, the nano- $\text{TiO}_2$  particles induced lipid peroxidation in the heart due to ROS production,  
562 which is similar to our findings regarding GSH and  $\text{H}_2\text{O}_2$  levels.  
563 Putting all of this information into context, as summarized in Figure 11, the Krebs cycle generates the  
564 NADH required for oxidative phosphorylation through the electron transport chain (complex I-IV, in

blue). This step-by-step transfer of electrons allows protons from the mitochondrial matrix to be transported uphill across the inner mitochondrial membrane, which forms a proton concentration gradient ( $\Delta\Psi_m$ ). Thus, free energy released during the oxidation of NADH is stored both as an electric potential and a proton concentration gradient across the inner membrane. The movement of protons back across the inner membrane, driven by this force, is coupled to the synthesis of ATP from ADP and  $P_i$  by the ATP synthase. During  $SiO_2$  nanoparticle perfusion (indicated by gray arrows), defects in the mitochondrial homeostasis contribute to the energetic mismatch observed (ATP depletion).  $SiO_2$  nanoparticles internalize and directly (dotted line) or indirectly produce ROS, such as the superoxide radical ( $O_2\cdot^-$ ), which is transformed to  $H_2O_2$  by superoxide dismutase (SOD) and then converted to  $H_2O$  using glutathione peroxidase activity (GPx), depleting the (GSH) and increasing oxidative stress. When a cardiomyocyte is depolarized,  $Ca^{2+}$  enters through the L-type calcium channels (LTCC). This  $Ca^{2+}$  triggers a subsequent release of  $Ca^{2+}$  that is stored in the sarcoplasmic reticulum (SR); through ryanodine receptors (RyR2), the  $Ca^{2+}$  released by the SR increases the intracellular  $Ca^{2+}$  (lower  $Ca^{2+}$  SR release), and then free  $Ca^{2+}$  binds to troponin C (TnC) and interacts with several proteins, which results in the sarcomere length being shortened (cell shortening decrease). In the relaxation phase, the SR sequesters  $Ca^{2+}$  using an ATP-dependent calcium pump (SERCA2a), which lowers the cytosolic  $Ca^{2+}$  concentration and removes calcium from the TnC, but because of the energy depletion, SERCA reduces its activity, which decreases the  $Ca^{2+}$  SR content.

### Clinical relevance

The World Health Organization estimated that there would be about 20 million cardiovascular disease deaths in 2015, accounting for 30% of all deaths worldwide. In this context, the likelihood of

cardiovascular diseases being associated with particulate air pollution is well documented. A series of scientific statements from the American Heart Association stressed that exposure to elevated levels of particulate matters is strongly linked with heart diseases, particularly when more than 75% of the total number of particles are nanoparticles (6, 17, 21). However, the correlation between heart disease and nanoscale particles is still being debated, and the related research conclusions lack consistency. Therefore, studying the cardiovascular toxicity of nanoscale particles is necessary and has profound scientific significance, particularly with regard to nanoparticle types, such as metal, metal-oxide, and carbon nanotubes, that have been reported to produce toxicity in other organs (35). To the best of our knowledge, we have demonstrated for the first time that SiO<sub>2</sub> nanoparticles impair the bioenergetics status and may consequently impact Ca<sup>2+</sup> handling and contraction in rat cardiomyocytes. The mechanism of cardiotoxicity for SiO<sub>2</sub> particles mimics the pathological mechanisms of a failing heart. These findings will be helpful in managing risk and providing guidance to reduce the hazardous effects of nanoscale particles. In addition, a better understanding of the mechanism through which nanoparticles produce cardiotoxicity could uncover novel avenues for avoiding the side effects associated with the use of these particles.

In summary, the findings of this study support the notion that SiO<sub>2</sub>-induced cardiomyocyte toxicity is strongly size dependent. 1) We showed differential, dose-dependent toxicity after 24 h incubation, with differential time-dependent cell death by necrosis (as shown by LDH leakage) and no activation of apoptosis. 2) We visualized, by confocal microscopy, an internalization phenomenon in these non-dividing, non-phagocytic primary-culture cell types, thus opening up a new field of study. 3) Our results showed the role of oxidative stress and the direct effect of SiO<sub>2</sub> particles on cell function: impaired Ca<sup>2+</sup> handling and a reduction in cell shortening. These effects were all due to mitochondrial malfunction,

which is shown as a drop in the membrane potential and ATP content (Figure 11). These data enable us to explore and carefully design new medical devices and clinical therapeutic protocols that take into account the advantages and disadvantages of nanoparticles, in particular SiO<sub>2</sub>.

## **Acknowledgements**

We thank Dr. Tzarara López-Luke and María Christian Álbora Cortés (Centro de Investigaciones en Óptica, CIO., Guanajuato. México), Lilia Magdalena Bautista Carrillo and Nayely Pineda Aguilar (Centro de Investigación en Materiales Avanzados S.C.), and Dr. Flavio Contreras-Torres (Laboratorio de Nanotecnología Ambiental, Tecnológico de Monterrey) for their technical support. We acknowledge Valeria Oropeza for the design of figure 11.

## **Source of Funding**

This work was partially supported by Endowed Chair in Cardiology (Tecnológico de Monterrey, 0020CAT131) as well as the CONACYT grant 151136, 133591, 269399 and Fronteras de la Ciencia grant (0682) and Xignus Research Fund. Postdoctoral fellowship (CONACYT, 290885 to C.E.G.B). SEM-EDS work was supported by grants from the National Center for Research Resources (5 G12RR013646-12) and the National Institute on Minority Health and Health Disparities (G12MD007591) from the National Institutes of Health.

## **Disclosure**

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

## References

1. **Al-Rasheed NM, Faddah LM, Mohamed AM, Abdel Baky NA, Al-Rasheed NM, Mohammad RA.** Potential impact of quercetin and idebenone against immuno- inflammatory and oxidative renal damage induced in rats by titanium dioxide nanoparticles toxicity. *J Oleo Sci* 62:961-971, 2013.
2. **Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, Bhattacharya R, Robertson JD, Rotello VM, Reid JM, Mukherjee P.** Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. *PLoS One* 6:e24374, 2011.
3. **Balderas-Villalobos J, Molina-Muñoz T, Mailloux-Salinas P, Bravo G, Carvajal K, Gómez-Viquez NL.** Oxidative stress in cardiomyocytes contributes to decreased SERCA2a activity in rats with metabolic syndrome. *Am J Physiol Heart Circ Physiol* 305: H1344-1353, 2013.
4. **Bers DM.** Cardiac excitation-contraction coupling. *Nature* 415:198-205, 2002. Review
5. **Blanco E, Hsiao A, Ruiz-Esparza GU, Landry MG, Meric-Bernstam F, Ferrari M.** Molecular-targeted nanotherapies in cancer: enabling treatment specificity. *Mol Oncol* 5:492-503, 2001.
6. **Brook RD, Rajagopalan S, Pope CA 3rd, Brook JR, Bhatnagar A, Diez-Roux AV, Holguin F, Hong Y, Luepker RV, Mittleman MA, Peters A, Siscovick D, Smith SC Jr, Whitset L, Kaufman JD.** Particulate matter air pollution and cardiovascular disease. *Circulation* 121:2331-2378, 2010.
7. **Campbell JL.** GUPIX and GUPIXWIN. 2005. <http://pixe.physics.uoguelph.ca/gupix/about/>.
8. **Du Z, Zhao D, Jing L, Cui G, Jin M, Li Y, Liu X, Liu Y, Du H, Guo C, Zhou X, Sun Z.** Cardiovascular toxicity of different sizes amorphous silica nanoparticles in rats after intratracheal instillation. *Cardiovasc Toxicol* 13:194-207, 2013.

9. **Duan J, Yu Y, Li Y, Li Y, Liu H, Jing L, Yang M, Wang J, Li C, Sun Z.** Low-dose exposure of silica nanoparticles induces cardiac dysfunction via neutrophil-mediated inflammation and cardiac contraction in zebrafish embryos. *Nanotoxicology* 9:1-11, 2015.
10. **Duan J, Yu Y, Li Y, Yu Y, Sun Z.** Cardiovascular toxicity evaluation of silica nanoparticles in endothelial cells and zebrafish model. *Biomaterials* 34:5853-5862, 2013.
11. **Dzeja PP, Terzic A.** Phosphotransfer networks and cellular energetics. *J Exp Biol* 206:2039-2047, 2003.
12. **Endoh M.** Cardiac Ca<sup>2+</sup> signaling and Ca<sup>2+</sup> sensitizers. *Circ J* 72:1915-1925, 2008.
13. **Farcal LR, Uboldi C, Mehn D, Giudetti G, Nativo P, Ponti J, Gilliland D, Rossi F, Bal-Price A.** Mechanisms of toxicity induced by SiO<sub>2</sub> nanoparticles of in vitro human alveolar barrier: effects on cytokine production, oxidative stress induction, surfactant proteins mRNA expression and nanoparticles uptake. *Nanotoxicology* 7:1095-1110, 2013.
14. **Fernández-Sada E, Silva-Platas C, Villegas CA, Rivero SL, Willis BC, García N, Garza JR, Oropeza-Almazán Y, Valverde CA, Mazzocchi G, Zazueta C, Torre-Amione G, García-Rivas G.** Cardiac responses to  $\beta$ -adrenoceptor stimulation is partly dependent on mitochondrial calcium uniporter activity. *Br J Pharmacol* 171:4207-4221, 2014.
15. **Gebel T, Marchan R, Hengstler JG.** The nanotoxicology revolution. *Arch Toxicol* 87:2057-2062, 2013.
16. **Gilardino A, Catalano F, Ruffinatti FA, Alberto G, Nilius B, Antoniotti S, Martra G, Lovisolo D.** Interaction of SiO<sub>2</sub> nanoparticles with neuronal cells: Ionic mechanisms involved in the perturbation of calcium homeostasis. *Int J Biochem Cell Biol* 66:101-111, 2015.



17. **Gold DR, Mittleman MA.** New insights into pollution and the cardiovascular system: 2010 to 2012. *Circulation* 127:1903-1913, 2013.
18. **Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, DeSimone JM.** The effect of particle design on cellular internalization pathways. *Proc Natl Acad Sci U S A* 105:11613-8, 2014.
19. **Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura Ki, Egashira K, Takeshita A.** Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. *Circ Res* 85:357-363, 1999.
20. **Jakob AM, Schmedake TA.** A Novel Approach to Monodisperse, Luminescent Silica Spheres. *Chem Mater* 18:3173-3175, 2006.
21. **Kumar P, Robins A.** A review of the characteristics of nanoparticles in the urban atmosphere and the prospects for developing regulatory controls. *Atmos Environ* 44:5035-5052, 2010.
22. **Kuum M, Kaasik A, Joubert F, Ventura-Clapier R, Veksler V.** Energetic state is a strong regulator of sarcoplasmic reticulum Ca<sup>2+</sup> loss in cardiac muscle: different efficiencies of different energy sources. *Cardiovasc Res* 83:89-96, 2009.
23. **Li Z, Barnes JC, Bosoy A, Stoddart JF, Zink JI.** Mesoporous silica nanoparticles in biomedical applications. *Chem Soc Rev* 41:2590-2605, 2012.
24. **Lin W, Huang YW, Zhou XD, Ma Y.** In vitro toxicity of silica nanoparticles in human lung cancer cells. *Toxicol Appl Pharmacol* 217:252-259, 2006.
25. **Lozano O, Mejia J, Masereel B, Toussaint O, Lison D, Lucas S.** Development of a PIXE analysis method for the determination of the biopersistence of SiC and TiC nanoparticles in rat lungs. *Nanotoxicology* 6:263-271, 2012.

26. **Lozano O, Mejia J, Piret JP, Saout C, Dogné JM, Toussaint O, Lucas S.** How does the deposited dose of oxide nanomaterials evolve in an in vitro assay? *Journal of Physics: Conference Series* 429:012013, 2013.
27. **Luo Z, Hu Y, Xin R, Zhang B, Li J, Ding X, Hou Y, Yang L, Cai K.** Surface functionalized mesoporous silica nanoparticles with natural proteins for reduced immunotoxicity. *J Biomed Mater Res A* 102:3781-3794, 2014.
28. **Maack C, Cortassa S, Aon MA, Ganesan AN, Liu T, O'Rourke B.** Elevated cytosolic Na<sup>+</sup> decreases mitochondrial Ca<sup>2+</sup> uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes. *Circ Res* 99:172-182, 2006.
29. **MacDonnell SM, García-Rivas G, Scherman JA, Kubo H, Chen X, Valdivia H, Houser SR.** Adrenergic regulation of cardiac contractility does not involve phosphorylation of the cardiac ryanodine receptor at serine 2808. *Circ Res* 102:e65-72, 2008.
30. **Miller CR, Bondurant B, McLean SD, McGovern KA, O'Brien DF.** Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. *Biochemistry* 37:12875-12883, 1998.
31. **Miragoli M, Novak P, Ruenraroengsak P, Shevchuk AI, Korchev YE, Lab MJ, Tetley TD, Gorelik J.** Functional interaction between charged nanoparticles and cardiac tissue: a new paradigm for cardiac arrhythmia?. *Nanomedicine (Lond)* 8:725-737, 2013.
32. **Monopoli MP, Walczyk D, Campbell A, Elia G, Lynch I, Bombelli FB, Dawson KA.** Physical–Chemical Aspects of Protein Corona: Relevance to in Vitro and in Vivo Biological Impacts of Nanoparticles. *J Am Chem Soc* 133:2525-2534, 2011.

- 714 33. **Napierska D, Thomassen LC, Lison D, Martens JA, Hoet PH.** The nanosilica hazard. *Part Fibre*  
715 *Toxicol* 7:39, 2010.
- 716 34. **Napierska D, Thomassen LC, Rabolli V, Lison D, Gonzalez L, Kirsch-Volders M, Martens JA,**  
717 **Hoet PH.** Size-dependent cytotoxicity of monodisperse silica nanoparticles in human  
718 endothelial cells. *Small* 5:846-853, 2009.
- 719 35. **Nel A, Xia T, Mädler L, Li N.** Toxic potential of materials at the nanolevel. *Science* 311:622-627,  
720 2006.
- 721 36. **Olson RD, Gambliel HA, Vestal RE, Shadle SE, Charlier HA Jr, Cusack BJ.** Doxorubicin cardiac  
722 dysfunction: effects on calcium regulatory proteins, sarcoplasmic reticulum, and  
723 triiodothyronine. *Cardiovasc Toxicol* 5:269-283, 2005.
- 724 37. **Qhobosheane M, Santra S, Zhang P, Tan W.** Biochemically functionalized silica nanoparticles.  
725 *Analyst* 126:1274-1278, 2001.
- 726 38. **Rabolli V, Thomassen LC, Princen C, Napierska D, Gonzalez L, Kirsch-Volders M, Hoet PH,**  
727 **Huaux F, Kirschhock CE, Martens JA, Lison D.** Influence of size, surface area and microporosity  
728 on the in vitro cytotoxic activity of amorphous silica nanoparticles in different cell types.  
729 *Nanotoxicology* 4:307-318, 2010.
- 730 39. **Rahman I, Kode A, Biswas SK.** Assay for quantitative determination of glutathione and  
731 glutathione disulfide levels using enzymatic recycling method. *Nature Protocols* 1:3159-3165,  
732 2006.
- 733 40. **Ruiz-Esparza GU, Cordero-Reyes AM, Youker KY, Serda RE, Yokoi K, Cara FE, Kirui DK, Paez-**  
734 **Mayorga J, Flores-Arredondo JH, Guerrero-Beltrán CE, García-Rivas G, Ferrari M, Blanco E,**

- Torre-Amione G.** A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells and accumulates in failing myocardium. *Eur J Heart Fail* 18:169-178, 2016.
41. **Savi M, Rossi S, Bocchi L, Gennaccaro L, Cacciani F, Perotti A, Amidani D, Alinovi R, Goldoni M, Aliatis I, Lottici PP, Bersani D, Campanini M, Pinelli S, Petyx M, Frati C, Gervasi A, Urbanek K, Quaini F, Buschini A, Stilli D, Rivetti C, Macchi E, Mutti A, Miragoli M, Zaniboni M.** Titanium dioxide nanoparticles promote arrhythmias via a direct interaction with rat cardiac tissue. *Early Hum Dev* 11:63, 2014.
42. **Serda RE, Godin B, Blanco E, Chiappini C, Ferrari M.** Multi-stage delivery nano-particle systems for therapeutic applications. *Biochim Biophys Acta* 1810:317-329, 2011.
43. **Serda RE, Gu J, Bhavane RC, Liu X, Chiappini C, Decuzzi P, Ferrari M.** The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. *Biomaterials* 30:2440-2448, 2009.
44. **Silva-Platas C, Guerrero-Beltrán CE, Carrancá M, Castillo EC, Bernal-Ramírez J, Oropeza-Almazán Y, González LN, Rojo R, Martínez LE, Valiente-Banuet J, Ruiz-Azuara L, Bravo-Gómez ME, García N, Carvajal K, García-Rivas G.** Antineoplastic copper coordinated complexes uncouple oxidative phosphorylation and induce mitochondrial permeability transition in cardiac mitochondria and cardiomyocytes. *J Bioenerg Biomembr* 48:43-54, 2016.
45. **Sohaebuddin SK, Thevenot PT, Baker D, Eaton JW, Tang L.** Nanomaterial cytotoxicity is composition, size, and cell type dependent. *Part Fibre Toxicol* 7:22, 2010.
46. **Sotiriou GA, Diaz E, Long MS, Godleski J, Brain J, Pratsinis SE, Demokritou P.** A novel platform for pulmonary and cardiovascular toxicological characterization of inhaled engineered nanomaterials. *Nanotoxicology* 6:680-690, 2012.

47. **Sun L, Li Y, Liu X, Jin M, Zhang L, Du Z, Guo C, Huang P, Sun Z.** Cytotoxicity and mitochondrial damage caused by silica nanoparticles. *Toxicol In Vitro* 25:1619-1629, 2011.
48. **Szebeni J, Alving CR, Rosivall L, Bünger R, Baranyi L, Bedöcs P, Tóth M, Barenholz Y.** Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. *J Liposome Res* 17:107-117, 2007.
49. **Tang L, Cheng J.** Nonporous silica nanoparticles for nanomedicine application. *Nano Today* 8:290-312, 2013.
50. **Tasciotti E, Liu X, Bhavane R, Plant K, Leonard AD, Price BK, Cheng MM, Decuzzi P, Tour JM, Robertson F, Ferrari M.** Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. *Nat Nanotechnol* 3:151-157, 2008.
51. **Wang Y, Zhao Q, Han N, Bai L, Li J, Liu J, Che E, Hu L, Zhang Q, Jiang T, Wang S.** Mesoporous silica nanoparticles in drug delivery and biomedical applications. *Nanomedicine* 11:313-327, 2015.
52. **Williams GS, Boyman L, Lederer WJ.** Mitochondrial calcium and the regulation of metabolism in the heart. *J Mol Cell Cardiol* 8:35-45, 2015.
53. **Willis BC, Salazar-Cantú A, Silva-Platas C, Fernández-Sada E, Villegas CA, Rios-Argaiz E, González-Serrano P, Sánchez LA, Guerrero-Beltrán CE, García N, Torre-Amione G, García-Rivas GJ, Altamirano J.** Impaired oxidative metabolism and calcium mishandling underlie cardiac dysfunction in a rat model of post-acute isoproterenol-induced cardiomyopathy. *Am J Physiol Heart Circ Physiol* 308:H467-477, 2015.

54. **Xue Y, Chen Q, Ding T, Sun J.** SiO<sub>2</sub> nanoparticle-induced impairment of mitochondrial energy metabolism in hepatocytes directly and through a Kupffer cell-mediated pathway in vitro. *Int J Nanomedicine* 9:2891-2903, 2014.
55. **Zarain-Herzberg A, García-Rivas G, Estrada-Avilés R.** Regulation of SERCA pumps expression in diabetes. *Cell Calcium* 56:302-310, 2014.

### Figure Captions

**Figure 1. Characterization of silica particles by SEM, XRD, DLS and zeta potential.** A) Representative Micro-SiO<sub>2</sub> micrograph showing size and morphology. Insert shows size distribution of Micro-SiO<sub>2</sub> obtained by FEG-SEM (n=100 particles). B) X-ray diffraction (XRD) analysis with the composition of the talline domains of Nano- and Micro-SiO<sub>2</sub>. All samples show the characteristic diffraction pattern of amorphous silica presenting a broad peak (10-30°) with a maximum around 22 °. C) The hydrodynamic sizes of Nano- and Micro-SiO<sub>2</sub> particles in ultrapure water D) The zeta potentials of Nano- and Micro-SiO<sub>2</sub> particles in ultrapure water. Colors black and gray corresponding to Micro-SiO<sub>2</sub> and Nano-SiO<sub>2</sub> respectively in each graphic.

**Figure 2. Viability of adult cardiomyocytes after 24 h exposure of SiO<sub>2</sub> particles and mechanism of cell death.**

A) Nano-SiO<sub>2</sub> and Micro-SiO<sub>2</sub> viability evaluated by Alamar Blue viability test. B) Representative dot-plots from flow cytometry with AnnexinV-PE-Cy7/Ghost Red 780 cell death analysis. A positive control of apoptosis cell death (56°C for 10 mins) is shown in comparison to CT, Nano-SiO<sub>2</sub> and Micro-SiO<sub>2</sub>

treated groups at 99.5  $\mu\text{g/ml}$ . C) The percentage of necrotic, live and apoptotic cells was quantified and is shown in the bar graph. D) Time-dependent cytotoxicity by Lactate dehydrogenase (LDH) leakage at 0-24 hours, in cultured cardiomyocytes with 24 hours incubation of Nano-SiO<sub>2</sub> and Micro-SiO<sub>2</sub> at its IC<sub>50</sub> (99.5  $\mu\text{g/ml}$  for Nano and 1,500  $\mu\text{g/ml}$  for Micro-SiO<sub>2</sub> particles). Values are mean  $\pm$  SEM, n=3-10; \*p<0.05; \*\*p<0.01; \*\*\*p<0.001 vs. control (CT).

**Figure 3. SiO<sub>2</sub> cellular association and internalization in adult rat cardiomyocytes.** Representative SEM micrographs showing: A) Nano-SiO<sub>2</sub> and B) Micro-SiO<sub>2</sub> individual and agglomerates/aggregates association to the cellular membrane. Representative SEM-EDS transversal cut images of C) untreated D) Nano-SiO<sub>2</sub> and E) Micro-SiO<sub>2</sub> particle internalization after 24h of incubation (99.5  $\mu\text{g/ml}$ ). F) Quantification of internalized SiO<sub>2</sub> particles by PIXE, as a function of time (for Nano 99.5  $\mu\text{g/ml}$  and Micro-SiO<sub>2</sub> 1,500  $\mu\text{g/ml}$ ). G) Representative confocal microscopy image of the F-Micro-SiO<sub>2</sub> shown as x, y and z-stacks. The cytoskeleton is shown in red and the brighter dots correspond to F-Micro-SiO<sub>2</sub> particles. The arrows indicate the SiO<sub>2</sub> particles in the cell. The symbol N (in panel G) marks the nucleus location in the cell. Values are mean  $\pm$  SD, a t-test was used as statistical analysis between Nano- and Micro-SiO<sub>2</sub>. Values are mean  $\pm$  SEM, n=3-5. \*p<0.05 vs. Nano; ‡p<0.05 vs. basal (time 0).

**Figure 4. Cardiomyocytes surface showing Silica particles by energy-dispersive X-ray spectroscopy (EDS).** Right, FEG-SEM images of A) Micro-SiO<sub>2</sub> and B) Nano-SiO<sub>2</sub> individual and agglomerates/aggregates association to the cellular membrane and C) an adult rat cardiomyocyte as a control sample. Left, the respective four EDS-images of elemental maps for carbon (red), sodium (cyan), silicon (magenta/yellow) and oxygen (green).

820

821 **Figure 5. Micro-SiO<sub>2</sub> internalization in adult myocytes.** A) Semi-quantitative increase in fluorescence in  
822 a dose-dependent manner of F-Micro-SiO<sub>2</sub> particles. B) Representative images from ventricular  
823 myocytes at the control (CT) condition and 150 µg/ml F-Micro-SiO<sub>2</sub> concentration. The cytoskeleton is  
824 shown in red and F-Micro-SiO<sub>2</sub> in green. Values are mean ± SEM, n=4-6. \*p<0.05 vs. CT.

825

826 **Figure 6. Cell shortening and Ca<sup>2+</sup> handling in cardiomyocytes treated with Nano- and Micro-SiO<sub>2</sub>**  
827 **particles.** The percentage of cell shortening before (CT) and after a 24 h treatment of Nano-SiO<sub>2</sub> and  
828 Micro-SiO<sub>2</sub> at its IC<sub>50</sub>. Values are mean ± SEM, n=15. \*\*p<0.001 vs. CT.

829

830 **Figure 7. Calcium transient characterization at basal condition and after β-adrenergic stimulation.** A-  
831 B) Representative images from field stimulated control and Nano-SiO<sub>2</sub> treated myocytes under basal  
832 conditions and after isoproterenol (ISO) perfusion, the arrow indicates the analyzed transient for semi-  
833 quantitative results. C) Peak Ca<sup>2+</sup> transient amplitude. D) Time to 50% of decay (T<sub>50%</sub>). Values are mean  
834 ± SEM. CT: n=22-33 cells/3 animals; Nano-SiO<sub>2</sub>: n=19-34 cells/3 animals \*p<0.05 vs. Nano-SiO<sub>2</sub>;  
835 ‡‡p<0.001 vs. Basal.

836

837 **Figure 8. Calcium sparks characterization in isolated myocytes.** A) Line scan images from control  
838 conditions (left) and after 24 hours incubation with Nano-SiO<sub>2</sub> (right). Surface plots can be seen above  
839 line scan images. Line profiles from selected 2 µm regions (black marks in line scan images) can be seen



on images. Pooled data describing B) spark frequency and C) amplitude. Values are mean  $\pm$  SEM, n=39 cells/3 animals/CT; 33 cells/3 animals/Nano-SiO<sub>2</sub>). \*p<0.05 vs. CT.

**Figure 9. Calcium content in the sarcoplasmic reticulum.** Representative images from caffeine-induced Ca<sup>2+</sup> transients from A) control (CT) and B) Nano-SiO<sub>2</sub> treated cardiomyocytes. Black arrow indicates caffeine application (10 mM). C) Pooled data for peak Ca<sup>2+</sup> transient amplitude (sarcoplasmic reticulum, SR Load; n=25 cells/3 animals/CT; 24 cells/3 animals/Nano-SiO<sub>2</sub>).

**Figure 10. Mitochondrial membrane potential, ATP content, ROS production, and GSH depletion.** Representative images from A) control (CT) and B) Nano-SiO<sub>2</sub> treated cardiomyocytes loaded with TMRE by confocal microscopy. Relative fluorescence from C) mitochondrial membrane potential (%) and D) ATP content (luminescence relative units, LRU) from control (CT) and Nano-SiO<sub>2</sub> treated cardiomyocytes. E) H<sub>2</sub>O<sub>2</sub> production and F) Glutathione content, in cultured cardiomyocytes with 24 hours incubation of Nano-SiO<sub>2</sub> at its IC<sub>50</sub>. Values are mean  $\pm$  SEM, n=10-11 cells (A-D); n=3 (E and F); \*p<0.05 vs. control (CT).

**Figure 11. Proposed mechanism of SiO<sub>2</sub>- induced cardiotoxicity.** Scheme of the suggested mechanism by which Nano-SiO<sub>2</sub> particles induces cardiotoxicity interfering with energetic status and Ca<sup>2+</sup> handling in cardiomyocytes. GSH/GSSG, reduced/oxidized glutathione; NCLX, Na<sup>+</sup>/Ca<sup>2+</sup> exchanger; O<sub>2</sub><sup>•-</sup>, superoxide radical; LTCC, L-type calcium channels; SR, sarcoplasmic reticulum; RyR2, ryanodine receptors; TnC, troponin C.





862 **Table**863 **Table 1. Characterization of silica particles by different techniques.**





<u>Particle</u> SiO <sub>2</sub>	<u>Crystallinity</u> (XRD)	<u>Purity</u> (EDS) (%)	<u>Size distribution</u>		<u>Surface charge</u> (Zeta Potential) (mV)
			<u>Feret diameter</u> (FEG-SEM) (nm)	<u>Hydrodynamic diameter</u> (DLS) (nm)	
Nano-SiO <sub>2</sub>	Amorphous	> 95%	7 *	91 ± 22 (water) 120 ± 25 (Tyrode) 220 ± 50 (M-199) 220 ± 106 (M-199 + BSA)	-24.1 (water) -22.0 (Tyrode) -21.6 (M-199) -20.8 (M-199 + BSA)
Micro-SiO <sub>2</sub>	Amorphous	> 95%	666 ± 32	712 ± 212 (water) 1106 ± 281 (Tyrode) 1190 ± 272 (M-199) 1281 ± 488 (M-199 + BSA)	-14.4 (water) -19.5 (Tyrode) -18.8 (M-199) -12.3 (M-199 + BSA)
F- Micro-SiO <sub>2</sub>	Amorphous	> 95%	611 ± 22	712 ± 153 (water) 712 ± 152 (Tyrode) 1484 ± 294 (M-199) 1484 ± 812 (M-199 + BSA)	-33.6 (water) -17.5 (Tyrode) -13.4 (M-199) -12.9 (M-199 + BSA)








864

## Cardiotoxicity of silica nanoparticles



- 865 XRD, X-ray Diffraction; EDS, Energy-dispersive X-ray spectroscopy; FEG-SEM, field emission gun
- 866 scanning electron microscope; DLS, Dynamic Light Scattering; ELS, Electrophoretic Light Scattering.
- 867 BSA: 5 mg/mL \* Size as referred by the provider's data sheet.











# A





# B




# C












**A****B**














**A****B****C**

**A****CT****B****Nano-SiO<sub>2</sub>****C****D****E****F**